Cogent Biosciences, Inc. (COGT) — Financial statements
Income statement, balance sheet, and cash flow for Cogent Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 5 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -5 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 270↑16.0% | 233↑33.9% | 174↑42.9% | 122↑117.5% | 56 | |
| General & Administrative Expenses | 64↑46.9% | 43↑25.9% | 34↑31.1% | 26↑33.5% | 20 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 64↑46.9% | 43↑25.9% | 34↑31.1% | 26↑33.5% | 20 | |
| Other Expenses | -5 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 329↑19.1% | 276↑32.6% | 208↑40.8% | 148↑95.7% | 76 | |
| Total Costs & Expenses | 333↑20.8% | 276↑32.6% | 208↑40.8% | 148↑95.7% | 76 | |
| Operating Results | ||||||
| Operating Income | -333↓20.8% | -276↓32.6% | -208↓40.8% | -148↓95.7% | -76 | |
| Depreciation & Amortization | 5↑6.2% | 4↑21.3% | 4↓39.0% | 6↑195.2% | 2 | |
| EBITDA | -329↓21.0% | -272↓32.8% | -205↓44.1% | -142↓93.0% | -74 | |
| EBIT | -333↓20.8% | -276↓32.6% | -208↓40.8% | -148↓95.7% | -76 | |
| Interest & Other Income | ||||||
| Net Interest Income | 12↓35.7% | 18↑38.3% | 13 | 0.00↓100.0% | 0.47 | |
| Interest Income | 15↓18.8% | 18↑38.3% | 13↑227.8% | 4↑754.2% | 0.47 | |
| Interest Expense | 3 | 0.00 | 0.00↓100.0% | 4 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 4↓78.0% | 20↑27.7% | 16↑106.9% | 8↑131.8% | 3 | |
| Income Before Tax | -329↓28.6% | -256↓33.0% | -192↓37.2% | -140↓94.0% | -72 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -329↓28.6% | -256↓33.0% | -192↓37.2% | -140↓94.0% | -72 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -329↓28.6% | -256↓33.0% | -192↓37.2% | -140↓94.0% | -72 | |
| Bottom-Line Net Income | -329↓28.6% | -256↓33.0% | -192↓37.2% | -140↓94.0% | -72 | |
| EPS (Basic) | -2.55↓3.7% | -2.46↓1.7% | -2.42↓7.1% | -2.26↓22.2% | -1.85 | |
| EPS (Diluted) | -2.55↓3.7% | -2.46↓1.7% | -2.42↓7.1% | -2.26↓22.2% | -1.85 | |
| Weighted Average Shares | 68↓34.9% | 104↑30.4% | 80↑35.6% | 59↑51.7% | 39 | |
| Weighted Average Diluted Shares | 68↓34.9% | 104↑30.4% | 80↑35.6% | 59↑51.7% | 39 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.